KRT18 as a Novel Biomarker of Urothelial Papilloma while Evaluating Low-Grade Papillary Urothelial Neoplasms: Bi-Center Analysis
Pathobiology · 27.08.2024 · 1-12
DOI: 10.1159/000540926 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Pathobiology, online erschienen am 27.08.2024. Verfasst von Minsun Jung und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Yonsei University College of Medicine, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Biomarkers, Tumor, Urothelium, Urinary Bladder Neoplasms, Keratin-18. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 50 Literaturangaben.
Abstract (Originalsprache)
Introduction
Although urothelial papilloma (UP) is an indolent papillary neoplasm that can mimic the morphology of low-grade papillary urothelial carcinoma (PUC), there is no immunomarker to differentiate reliably these two entities. In addition, the molecular characteristics of UP are not fully understood.
Methods
We conducted an in-depth proteomic analysis of papillary urothelial lesions (n = 31), including UP and PUC along with normal urothelium. Protein markers distinguishing UP and PUC were selected with machine learning analysis, followed by internal and external validation using immunohistochemistry.
Results
In the proteomic analysis, UP and PUC showed overlapping proteomic profiles. We identified EHD4 and KRT18 as candidate diagnostic biomarkers of UP. Through immunohistochemical validation in two independent cohorts (n = 120), KRT18 was suggested as a novel UP diagnostic marker, able to differentiate UP from low-grade PUC. We also found that 3.5% of patients with UP developed urothelial carcinoma in subsequent resections, supporting the malignant potential of UP. KRT18 downregulation was significantly associated with UPs subsequently progressing to urothelial carcinoma, following their initial diagnosis.
Conclusion
This is the first study that successfully revealed UPs comprehensive proteomic landscape, while it also identified KRT18 as a potential diagnostic biomarker of UP.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, Yonsei University College of Medicine, Seoul, Republic of Korea.
- Department of Pathology, Konkuk University Medical Center, Konkuk University School of Medicine, Seoul, Republic of Korea.
- Department of Pathology, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, Republic of Korea.
- Transdisciplinary Department of Medicine and Advanced Technology, Seoul National University Hospital, Seoul, Republic of Korea.
- Proteomics Core Facility, Biomedical Research Institute, Seoul National University Hospital, Seoul, Republic of Korea.
- Department of Pathology, Seoul National University Hospital, Seoul, Republic of Korea.
Zitieren
APA
Jung, M., Kim, B., Lee, J. S., Kim, J. Y., Han, D., Kim, K., Yang, S., Kim, E. N., Kim, H., Nikas, I. P., Yang, S., Moon, K. C., Lee, H., & Ryu, H. S. (2024). KRT18 as a Novel Biomarker of Urothelial Papilloma while Evaluating Low-Grade Papillary Urothelial Neoplasms: Bi-Center Analysis. Pathobiology, 1-12. https://doi.org/10.1159/000540926
Vancouver
Jung M, Kim B, Lee JS, Kim JY, Han D, Kim K, et al. KRT18 as a Novel Biomarker of Urothelial Papilloma while Evaluating Low-Grade Papillary Urothelial Neoplasms: Bi-Center Analysis. Pathobiology. 2024:1-12. doi:10.1159/000540926
BibTeX
@article{Jung2024,
author = {Jung, Minsun and Kim, Bohyun and Lee, Jae Seok and Kim, Jun Yong and Han, Dohyun and Kim, Kwangsoo and Yang, Sunah and Kim, Eun Na and Kim, Hyeyooon and Nikas, Ilias P and Yang, Sohyeon and Moon, Kyung Chul and Lee, Hyebin and Ryu, Han Suk},
title = {KRT18 as a Novel Biomarker of Urothelial Papilloma while Evaluating Low-Grade Papillary Urothelial Neoplasms: Bi-Center Analysis},
journal = {Pathobiology},
year = {2024},
pages = {1--12},
doi = {10.1159/000540926}
}
EUVIMED